SelectScience
Join Free
Accelerating Science
NewsClinical Diagnostics

Dako Announces Collaboration on Development of PD-L1 Companion Diagnostic Test for Investigational Cancer Drug Opdivo® (nivolumab)

Dako Corp.
24 Feb 2015

Industry news

Dako, an Agilent Technologies company ("Agilent") and a worldwide provider of cancer diagnostics, and ONO PHARMACEUTICAL CO., LTD. ("ONO"), has announced a new partnership to develop a potential diagnostic test specifically for use with Opdivo in the treatment of non-small cell lung cancer (NSCLC). This test is being investigated for its diagnostic utility to determine which patients are most likely to respond to Opdivo.

Lung cancer is the most common cause of cancer-related mortality worldwide, and is responsible for more than 1.5 million deaths per year1. The demand for personalized medicine continues to increase as it may provide a way to both improve patient care and better manage health care costs by targeting treatment to the individuals most likely to benefit from it.

"We are pleased to be chosen as ONO’s partner for the development of a companion diagnostic test for this promising drug. Today’s announcement follows several other collaborative agreements in the companion diagnostics area by Agilent’s Dako business," said Jacob Thaysen, president of Agilent's Diagnostics and Genomics Group.

"We are delighted to collaborate with Dako, a global leader in diagnostics, and this partnership contributes to value maximization of Opdivo," said Gyo Sagara, president, representative director and CEO, ONO.
The financial details of the agreement were not disclosed.


References:
1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: globocan.iarc.fr, accessed on 21/November/2014.

Links

Dako Corp.Company website

Tags

Genome AnalysisGenomics, the study of genomes, includes functional genomics, evolutionary genomics and comparative genomics. There are many genomic technologies such as DNA sequencing of whole genomes, computational biology and bioinformatics. DNA and nucleic acids must be isolated and concentrated from cells for analysis with kits, automated analyzers and software. Other useful technologies for studying genomics include PCR, microarrays and electrophoresis.Clinical GeneticsMolecular Genetics covers the analysis of hereditary genetic disease and chromosomal abnormalities. Genetics can be analysed using DNA, RNA, and protein microarrays, PCR, RT PCR and DNA sequencing. Genetic equipment includes genetic workstations, thermal cyclers, cooling blocks and electrophoresis products. Diagnostic kits are used for DNA / RNA extraction and purification.Cancer DiagnosticsThere are a wide variety of diagnostic tests for cancer available, and this range continues to expand as our knowledge of cancer improves. Current diagnostic methods include biopsy, imaging and blood tests for known biomarkers. New methods in research development include liquid biopsies and cancer breathalyzers.Lung CancerLung cancer is a leading cause of cancer-related deaths worldwide, often diagnosed at an advanced stage. Research focuses on early detection, targeted therapies, and personalized treatment strategies. Explore lung cancer research and diagnostic products in our peer-reviewed product directory; compare products, check reviews, and get pricing directly from manufacturers.Companion DiagnosticsCompanion diagnostics are tests, often <i>in vitro</i>, that are used to determine whether a therapeutic product will be safe and effective for use on an individual. They also identify which patients will benefit most from them. Companion diagnostic tests are often developed in conjunction with the pharmaceutical industry.

Related articles